scispace - formally typeset
D

David S. Bredt

Researcher at Johnson & Johnson

Publications -  224
Citations -  63974

David S. Bredt is an academic researcher from Johnson & Johnson. The author has contributed to research in topics: Nitric oxide synthase & Nitric oxide. The author has an hindex of 107, co-authored 223 publications receiving 62332 citations. Previous affiliations of David S. Bredt include Johns Hopkins University & Georgetown University Medical Center.

Papers
More filters
Journal ArticleDOI

α7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins

TL;DR: The authors identify anti-apoptotic, Bcl-2 family proteins as enhancers of α7 nAChR assembly, acting through an intracellular BH3-like domain during receptor biogenesis in the endoplasmic reticulum.
Journal ArticleDOI

MALS-3 regulates polarity and early neurogenesis in the developing cerebral cortex.

TL;DR: The results suggest that MALS-3 plays a role in maintaining apicobasal polarity and is required for normal neurogenesis in the developing cortex.
Journal ArticleDOI

NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy.

TL;DR: In certain vascular beds, regulation of vessel tone by NO does not require the endothelium but instead relies on neuronal activity, and sildenafil (Viagra) enhances erectile function by specifically augmenting vasodilatory actions of neuron-derived NO.
Journal ArticleDOI

Nicotinic acetylcholine receptor redux: Discovery of accessories opens therapeutic vistas.

TL;DR: Nicotinic ACh receptors (nAChRs) were the first ion channels to be isolated and have been identified molecules that control nAChR biogenesis, trafficking, and function as mentioned in this paper.
Journal ArticleDOI

Targeted disruption of PSD-93 gene reduces platelet-activating factor-induced neurotoxicity in cultured cortical neurons

TL;DR: It is reported here that PSD-93 colocalizes and interacts with the NMDA receptor and neuronal nitric oxide synthase in cultured cortical neurons and is involved in theNMDA receptor--nitric oxide-mediated pathological processing of neuronal damage triggered via platelet--activating factor receptor activation.